FCF Margin % is calculated as Free Cash Flow divided by its Revenue. HCW Biologics's Free Cash Flow for the
three
months ended in Mar. 2026 was $-1.58 Mil. HCW Biologics's Revenue for the
three
months ended in Mar. 2026 was $6.54 Mil. Therefore, HCW Biologics's FCF Margin % for the quarter that ended in Mar. 2026 was -24.07%.
The historical rank and industry rank for HCW Biologics's FCF Margin % or its related term are showing as below:
HCWB'
s FCF Margin % Range Over the Past 10 Years
Min: -24800 Med: -564.43 Max: -173.71
Current: -173.71
During the past 7 years, the highest FCF Margin % of HCW Biologics was -173.71%. The lowest was -24800.00%. And the median was -564.43%.
HCWB's FCF Margin % is ranked worse than 59.17% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs HCWB: -173.71
HCW Biologics FCF Margin % Related Terms
HCW Biologics FCF Margin % Historical Data
* Premium members only.
The historical data trend for HCW Biologics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HCW Biologics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where HCW Biologics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics (HCWB) has a FCF Margin % of -24.07% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on HCW Biologics and its competitors. According to the industry distribution chart, HCW Biologics ranks #568 out of 960 companies in the Biotechnology industry, placing it in the top 59.2%.
Is HCW Biologics' FCF Margin % too high?
HCW Biologics' current FCF Margin % is -24.07%. Based on the distribution chart, HCW Biologics ranks #568 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' FCF Margin % compare to MTVA and INTI?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #568 out of 960 companies for FCF Margin %. This places HCW Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on HCW Biologics and its competitors. HCW Biologics's current FCF Margin % is -24.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $7.29, compared to a current price of $1.15 — trading 84.3% below its estimated fair value. The current FCF Margin % is -24.07%. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For HCW Biologics (HCWB), the current FCF Margin % is -24.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $1.15 is trading 84.3% below its estimated GF Value™ of $7.29.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
FCF Margin %: -24.07%
GF Value™: $7.29 vs. price of $1.15 (84.3% below fair value)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score
Get the complete analysis for HCWB
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
